IMM - Immutep Limited
- Thread starter ozewolf
- Start date
- Joined
- 28 January 2008
- Posts
- 104
- Reactions
- 0
Re: PRR on the MOVE...
Agreed totally. There is usually considerable risk in bio-techs, but my god, the potential of this baby is insane. The technology involved and extent of the trials to date is impressive. I noticed the days' candle finished today with buying pressure on significantly large volume. Could be exciting times in near future. Shares aside, a significant Aussie breakthrough in cancer research would be amazing.
Looks PRR is showing positive movement since last anouncement and market
is proving same...
Time to accumulate
Agreed totally. There is usually considerable risk in bio-techs, but my god, the potential of this baby is insane. The technology involved and extent of the trials to date is impressive. I noticed the days' candle finished today with buying pressure on significantly large volume. Could be exciting times in near future. Shares aside, a significant Aussie breakthrough in cancer research would be amazing.
Media speculation suggests PRR is a stock to hold.
Prima BioMed (PRR) 0.9c
CRITERION: Tim Boreham | March 12, 2009
Article from: The Australian
FROM the miracles-do-happen file comes this provident yarn of a $3.4 million market cap tiddler that has secured $12 million of funding for further development of its ovarian cancer drug, CVac.
A day traders' favourite, Prima had been close to biting the dust, with a mere $750,000 in the bank and no major holder to tap.
Investment bank Fortrend Securities has filled the breach with an equity facility. Details are scarce, but the funds can be drawn down at Prima's discretion over the next three years based on the prevailing share price. For Prima's 1500 investors this means that unless the share price improves lickety-split, they'll get a heavily diluted share of the spoils.
As Prima CEO Martin Rogers argues, that's better than holding 100 per cent of an entity that was likely to have "gone to dust" without the funding. He adds that retail holders could have provided funding via a share-purchase plan, but the take-up was underwhelming.
The CVac vaccine -- targeted for cancers with a high morbidity rate -- offers an entree into a wider ovarian cancer market worth $US2.1 billion ($3.27 billion) annually (biotech PR 101: spruik the billion-dollar size of the existing potential market).
Prima's earlier trials resulted in four out of 21 patients (19 per cent) responding to the treatment. While this doesn't sound like a brilliant rate, we're talking about very sick patients.
The next step is an FDA-approved phase2b/3 trial. The submission paperwork alone costs $US135,000, but Rogers expects the $12 million to be more than enough to get to registration stage.
Biotech Daily analyst Marc Sinatra gave up on Prima "many moons ago". He says that while the facility isn't ideal, it's not "death spiral" financing such as resetting secured convertible notes. "This deal demonstrates there's a little bit of capital around for less than perfect or higher risk assets," he says.
Criterion rates Prima a hold. The stock is also good for speculative fun, as it's subject to violent intraday fluctuations.
Prima boasts a bankable signature in the guise of Gardasil (cervical cancer vaccine) hero Ian Frazer, who heads the scientific committee.
source:
http://www.theaustralian.news.com.au/story/0,25197,25173368-23634,00.html
Prima BioMed (PRR) 0.9c
CRITERION: Tim Boreham | March 12, 2009
Article from: The Australian
FROM the miracles-do-happen file comes this provident yarn of a $3.4 million market cap tiddler that has secured $12 million of funding for further development of its ovarian cancer drug, CVac.
A day traders' favourite, Prima had been close to biting the dust, with a mere $750,000 in the bank and no major holder to tap.
Investment bank Fortrend Securities has filled the breach with an equity facility. Details are scarce, but the funds can be drawn down at Prima's discretion over the next three years based on the prevailing share price. For Prima's 1500 investors this means that unless the share price improves lickety-split, they'll get a heavily diluted share of the spoils.
As Prima CEO Martin Rogers argues, that's better than holding 100 per cent of an entity that was likely to have "gone to dust" without the funding. He adds that retail holders could have provided funding via a share-purchase plan, but the take-up was underwhelming.
The CVac vaccine -- targeted for cancers with a high morbidity rate -- offers an entree into a wider ovarian cancer market worth $US2.1 billion ($3.27 billion) annually (biotech PR 101: spruik the billion-dollar size of the existing potential market).
Prima's earlier trials resulted in four out of 21 patients (19 per cent) responding to the treatment. While this doesn't sound like a brilliant rate, we're talking about very sick patients.
The next step is an FDA-approved phase2b/3 trial. The submission paperwork alone costs $US135,000, but Rogers expects the $12 million to be more than enough to get to registration stage.
Biotech Daily analyst Marc Sinatra gave up on Prima "many moons ago". He says that while the facility isn't ideal, it's not "death spiral" financing such as resetting secured convertible notes. "This deal demonstrates there's a little bit of capital around for less than perfect or higher risk assets," he says.
Criterion rates Prima a hold. The stock is also good for speculative fun, as it's subject to violent intraday fluctuations.
Prima boasts a bankable signature in the guise of Gardasil (cervical cancer vaccine) hero Ian Frazer, who heads the scientific committee.
source:
http://www.theaustralian.news.com.au/story/0,25197,25173368-23634,00.html
Just wondering when this "violent intraday fluctuations" is happening next?
According to this arcticle it states:
Criterion rates Prima a hold. The stock is also good for speculative fun, as it's subject to violent intraday fluctuations.
source:
http://www.theaustralian.news.com.au/story/0,25197,25173368-23634,00.html
According to this arcticle it states:
Criterion rates Prima a hold. The stock is also good for speculative fun, as it's subject to violent intraday fluctuations.
source:
http://www.theaustralian.news.com.au/story/0,25197,25173368-23634,00.html
Re: PRR on the MOVE...
I very much hope you are still accumulating this stock at current levels. I am sure some prelimanary results in reagrds to the CVac cancer trials will be announced to the market in due course.
Looks PRR is showing positive movement since last anouncement and market
is proving same...
Time to accumulate
I very much hope you are still accumulating this stock at current levels. I am sure some prelimanary results in reagrds to the CVac cancer trials will be announced to the market in due course.
I'm curious about what the market depth is showing on PRR at the moment.
To my inexperienced eye, it looks like an overwhelming demand for stock. I'm trying to find the reason for this.
Anyone else care to take a look, perhaps post a theory?
Cheers,
togs
To my inexperienced eye, it looks like an overwhelming demand for stock. I'm trying to find the reason for this.
Anyone else care to take a look, perhaps post a theory?
Cheers,
togs
andione1983
Danger Will Robinson, Danger
- Joined
- 2 February 2009
- Posts
- 41
- Reactions
- 0
looks like a good opportunity, if you want something risky, but which has a fairly strong possibility of doing something, it might be worth a try, so i am umping in with 1000.00 at .016C each
Been sitting on this for some time and patience is finaly paying itself off...
Huge upside in 2009 (I believe)...
andione1983
Danger Will Robinson, Danger
- Joined
- 2 February 2009
- Posts
- 41
- Reactions
- 0
has anyone else of Primas research this year are they looking good at this stage? Obviously the government has some hopes that they have some business potential here?
you have done well so far and I believe there is even more upside waiting for ya
I don't think that there is anything to worry about at current levels...good luck
andione1983
Danger Will Robinson, Danger
- Joined
- 2 February 2009
- Posts
- 41
- Reactions
- 0
UP 30% in the last 2 days... now .027 so looking good i think? what are your thoughts.....................................
andione1983
Danger Will Robinson, Danger
- Joined
- 2 February 2009
- Posts
- 41
- Reactions
- 0
PRR is looking all good so far (I think)...
and much more upside especially with more positive announcements...
GO PRR
.035 at close of business today!!
but why hasnt the company released any news releases as to why they have gained so much? whats the go?- Joined
- 2 April 2009
- Posts
- 23
- Reactions
- 0
BioTechnologyNews.net
Prima soars on Dendreon announcement
andione1983: Maybe this will help you with regards to "the go."
Prima soars on Dendreon announcement
andione1983: Maybe this will help you with regards to "the go."